Quantum Simulation
Using quantum systems to understand quantum systems: the capability most likely to deliver the first genuine commercial quantum advantage — and where your industry's next molecule, material, or catalyst may come from.
1. What it is, in one paragraph
2. How it actually works, without the physics lecture
3. The current state: scientific utility now, commercial advantage next
4. The platform landscape: what each approach does well
5. Where it matters for your business, by sector
6. What implementing quantum sensing actually looks like
7. The honest economics
8. A practical roadmap for serious adopters
9. Common pitfalls to avoid
10. When to act — ahead of the curve, but with discipline
11. The strategic significance
11. Beyond the sensor: the longer horizon
Quantum Simulation is the use of a controllable quantum system — a collection of cold atoms, trapped ions, superconducting qubits, photons — to model the behaviour of another quantum system that is hard or impossible to study by classical means. That "other system" is typically a molecule, a new material, a chemical reaction, or a magnetic phase of matter. The logic is simple: the universe is fundamentally quantum-mechanical, and simulating quantum behaviour on a classical computer costs exponentially more memory and time as the system grows. A quantum computer, by construction, works in the same space as the thing being simulated, so the cost scales polynomially. This is where the credible "exponential speedup" actually lives — not in optimisation, not in machine learning, but in chemistry, materials, and condensed-matter physics. It is also where the first commercially useful quantum advantage is most likely to appear in this decade.
If you are in pharmaceuticals, chemicals, materials, energy storage, or advanced manufacturing, this is the quantum pillar whose trajectory should be on your strategic radar.
Quantum simulation comes in two flavours. Understanding the distinction is the single most useful piece of technical literacy for a business leader in this space.
Digital quantum simulation uses a general-purpose quantum computer — the same hardware we described in the Quantum Computing pillar — running a circuit that encodes the target system's Hamiltonian (its physics) and evolves it step by step. This is flexible (you can simulate anything in principle) but demands significant circuit depth and qubit counts, which puts it at the edge of what today's noisy hardware can do. The workflow is almost always hybrid: a classical computer prepares parameters, the quantum computer runs a short circuit, the classical computer analyses the result and updates the parameters, and the loop repeats. Variational Quantum Eigensolver (VQE) is the archetype.
Analog quantum simulation uses a purpose-built quantum device whose natural physics directly matches the system you want to study. Arrays of neutral atoms held in optical tweezers (Pasqal, QuEra, Atom Computing), chains of trapped ions (Quantinuum, IonQ), and superconducting quantum lattices are the leading platforms. The simulator does not "compute" in the gate-model sense; it becomes a physical analogue of the target system. This is less flexible — each device suits certain classes of problems — but can handle problem sizes far beyond what digital quantum computers can reach today. Analog simulators with hundreds of qubits are already producing scientific results that classical simulation cannot match.
Four practical consequences for business decisions.
First, analog simulators are further ahead than digital ones for many problems. Some of the most impressive genuine quantum results of the past two years — condensed-matter-physics phase transitions, lattice-gauge-theory simulations, magnetism studies — have come from analog platforms with hundreds of atoms, not from 1,000-qubit digital machines.
Second, hybrid workflows are not a limitation; they are the architecture. Real quantum simulation of real chemistry will, for the foreseeable future, combine classical high-performance computing (for what it does best: setting up, pre-processing, post-processing, and handling the parts of the problem where classical methods already work well) with quantum hardware (for the specific sub-problem where quantum genuinely helps). Treating quantum as a co-processor is the correct mental model.
Third, the edge arrives gradually, by problem class. Unlike quantum computing's general-purpose story, quantum simulation will likely cross the commercial-advantage threshold for specific problem types (small strongly-correlated molecules, certain lattice models, specific catalyst classes) before others. The first "quantum utility" in a commercial setting almost certainly comes from simulation, not from cryptography-breaking or from generic optimisation.
Fourth, the right question is not "when does quantum beat classical?" but "for which problems, in which regime, with what accuracy?" Classical methods (DFT, coupled-cluster, DMRG, tensor networks, classical ML surrogates) keep improving. The frontier moves in both directions. What matters commercially is whether, for your molecule or your material, the quantum-enhanced workflow answers a question faster, cheaper, or more accurately than the best available classical alternative.
Quantum simulation is further along than quantum computing in general, for one reason: simulating quantum systems is the use case Feynman proposed when he imagined quantum computers in 1982, and the algorithmic community has had 40 years to focus on it.
Where the field stands, honestly:
Analog simulation has crossed the "classical limit" in several scientific problems. Papers in Nature, Science, and PRX in the past three years have reported 200–300-atom Rydberg simulations of lattice models, gauge theories, and phase transitions that classical computation cannot match in accuracy at the same scale. These are scientific, not commercial, results — but they are real.
Digital simulation has produced convincing demonstrations on small molecules. VQE and its descendants have been run on molecules up to ~20 electrons, showing the workflow works even if it doesn't yet beat the best classical methods.
"Quantum utility," defined as a quantum result being the best available answer to a well-defined scientific problem, has probably been achieved in niche cases. "Quantum advantage for a commercially valuable problem" has not yet been achieved and remains the central prize in the field.
Every major chemical, pharmaceutical, and materials company has at least a small quantum-simulation team. BASF, Merck, Roche, Boehringer-Ingelheim, JSR, Dow, Covestro, Mitsubishi Chemical, AstraZeneca, Pfizer, Sanofi, GSK, and others have named programmes. Automotive and energy companies (BMW, VW, Daimler, TotalEnergies, ExxonMobil, Eni) are engaged in battery and catalyst programmes.
Credible timelines for first commercial advantage in chemistry / materials simulation: 2–5 years for niche cases, 5–10 years for routine industrial use.
The field has been disciplined about distinguishing what is demonstrated from what is promised. This is not a space where major companies are claiming revenue from quantum simulation today; it is a space where they are positioning to be ready when it arrives.
You will not choose a platform; your use case will. But the landscape matters for vendor selection and for understanding proposals.
Neutral-atom analog simulators (Pasqal, QuEra, Atom Computing). Arrays of individually-trapped neutral atoms in optical tweezers, excited to Rydberg states to create controllable interactions. Currently operating with 100–1,200+ atoms. Sweet spot: lattice models, magnetism, optimisation problems that map naturally to the Rydberg interaction graph, specific quantum chemistry mappings. Increasingly also capable of digital gate-based operation. Leading European platform (Pasqal is a French company with substantial EU programmes). Several cloud-accessible services are live.
Trapped-ion digital simulators (Quantinuum, IonQ). Chains of ions manipulated with laser pulses. Very high fidelity (>99.9% on two-qubit gates), slower operations, smaller qubit counts (typically 20–56 today). Excellent for depth-sensitive quantum chemistry circuits and for algorithms where gate errors would overwhelm larger but noisier platforms.
Superconducting digital simulators (IBM, Google, Rigetti, IQM). Same hardware stack as general-purpose quantum computing. Thousands of physical qubits at IBM, running circuits depth-limited by noise. VQE and related chemistry workflows are the dominant simulation application. Will transition toward fault-tolerant simulation as error correction matures.
Photonic quantum simulators (Xanadu, PsiQuantum-derived platforms). Gaussian boson sampling and related photonic architectures can simulate specific molecular vibration problems directly. Niche but real; Xanadu's Borealis machine is cloud-accessible.
Emerging and research-stage platforms: molecular simulators based on NMR, measurement-based photonic approaches, nitrogen-vacancy-based simulators, spin-qubit arrays. Watch but not yet procure.
Software and application layer. Equally important to the hardware. Key players:
Chemistry-focused: Classiq, Qunasys, Good Chemistry, Menten AI, QC Ware, Zapata (now defunct, a useful cautionary tale), Kvantify, 1QBit.
Open-source frameworks: PennyLane (Xanadu), Qiskit Nature (IBM), OpenFermion, PyQuante, Quimb, tequila.
Hyperscaler layers: AWS Braket, Azure Quantum, IBM Quantum — all of which support chemistry workflows through their SDKs and often package the above.
The software layer is often where your actual productivity lives, and the vendors who package quantum simulation into usable industrial workflows are increasingly the ones winning real customer engagements.
Quantum simulation's value is concentrated in industries whose products or processes are ultimately governed by quantum-mechanical behaviour at the molecular, atomic, or electronic scale. That is a narrower set than it sounds.
Pharmaceuticals and life sciences. The leading candidate for commercial quantum simulation value. Drug discovery depends on accurate modelling of small-molecule interactions with proteins, metal-containing enzyme active sites, and strongly-correlated electronic systems that classical methods struggle with. Fractional improvements in predictive accuracy translate into billions of dollars in R&D savings across the industry. Every top-20 pharma has an active quantum-simulation engagement. Expect the first pharma-relevant quantum result — a molecule designed or optimised with demonstrable quantum contribution — within this decade.
Chemicals and catalysts. The Haber-Bosch ammonia process alone consumes 1–2% of world energy; a better catalyst discovered through quantum simulation would reshape both the chemical industry and the global energy balance. Battery materials, fuel-cell catalysts, CO₂-reduction catalysts, and industrial hydrogenation catalysts all sit at the same frontier. Major chemical companies (BASF, Covestro, Dow, Sinopec, Mitsubishi Chemical, JSR) have dedicated quantum programmes. Near-term real-world impact is most likely here.
Materials science and semiconductors. New materials for magnets, superconductors, thermoelectrics, photovoltaics, quantum technologies themselves, and advanced semiconductor processes all involve electronic-structure problems at the edge of classical tractability. Samsung, TSMC, Intel, Applied Materials, and most major-materials companies have quantum programmes. Expect commercial applications in materials screening and discovery, probably first in niches (specialised alloys, quantum-device materials, exotic magnets) before broader impact.
Energy storage and generation. Battery cathodes and anodes, solid-state electrolytes, next-generation photovoltaics, fuel-cell membranes, and thermoelectric materials are all quantum-simulation problems. Automotive and energy companies (BMW, VW, TotalEnergies, Eni, Mitsubishi) have live programmes, often in consortium with materials companies and quantum software providers.
Agrochemicals and fertilisers. Beyond the headline Haber-Bosch question, precision herbicide, pesticide, and fertiliser design increasingly involves molecular simulation at the frontier of classical accuracy. Bayer, Syngenta, BASF, and Corteva all operate in this space.
Cosmetics, consumer goods with materials-science depth, speciality polymers, paints and coatings. Niche but real for companies with significant molecular-science R&D budgets.
Manufacturing and aerospace intersect quantum simulation through advanced-materials and alloys programmes: lighter structural alloys, high-temperature materials, fatigue-resistant composites. Slower uptake than pharma or chemicals, but present.
Most other sectors — finance, retail, telecommunications, media, logistics, insurance, professional services — do not have quantum-simulation use cases. The distinction between quantum simulation (chemistry/materials) and quantum computing (general-purpose) matters: industries whose problems are optimisation, ML, or data-driven rather than molecular are not in simulation's addressable market.
Unlike quantum sensing, quantum simulation is not yet a commercial product you buy. It is a capability you build — typically in partnership with a software provider, a hardware vendor, and your own domain scientists. Here is what that build typically involves.
The problem-framing stage. The single highest-leverage activity. Quantum simulation is only valuable where the underlying problem is (a) genuinely hard for classical methods, (b) small enough to fit on near-term quantum hardware, and (c) structured such that a quantum algorithm has a credible advantage. Very few real industrial problems satisfy all three. The discovery process — usually weeks of joint work between your chemists/materials scientists and a quantum-algorithms team — produces a short list of candidate problems with honest assessments of their quantum-fitness.
The hybrid workflow stage. Once a candidate problem is selected, the workflow is built: classical pre-processing (geometry, basis set, active-space selection), quantum circuit design (what runs on the quantum machine), classical post-processing (extraction of the chemical or material property of interest), and a benchmark against the best available classical method. This is a software engineering and computational science project, typically 6–12 months in duration.
The platform choice. Each problem has a best-fit platform. Small high-accuracy chemistry may map best to trapped ions; lattice and magnetism to Rydberg arrays; larger noisy workflows to superconducting; vibration problems to photonic. A serious programme maintains access to multiple platforms, usually through cloud APIs, and selects per problem. Single-vendor lock-in at this stage is imprudent.
The classical co-processor. An often-overlooked fact: effective quantum simulation requires substantial classical compute. GPUs for variational optimisation, classical simulators for verification (up to 30–40 qubits can still be verified classically), and classical chemistry software (PySCF, Gaussian, VASP, ORCA, etc.) for framing the problem. Treat the quantum machine as one node in a heterogeneous HPC pipeline, not as a standalone computer.
The team you need. Typically: domain experts (chemists, materials scientists, crystallographers) from the business; a quantum algorithms specialist (internal or external); a software engineer comfortable with Python and scientific computing; and — if the programme is serious — a dedicated relationship with one or more quantum platform vendors. You do not need in-house quantum physicists; you do need domain scientists who have been upskilled in quantum methods, which is a 6–12 month investment per person.
Software partnerships. For most industrial clients, direct use of IBM Qiskit or PennyLane is not the right entry point. Working with a chemistry-specialised quantum software company (Classiq, Qunasys, Good Chemistry, Menten AI, QC Ware, Kvantify) dramatically shortens time-to-useful-result, because those companies package the algorithmic choices, the platform integrations, and the classical-quantum orchestration into industrial workflows.
A meaningful quantum-simulation engagement — not a one-off pilot, but a sustained capability in a chemical, pharmaceutical, or materials company — looks economically like this.
Entry-level literacy and exploration: €50K–€150K over 6 months. Focused on identifying candidate problems, training a small domain team, engaging with a quantum software vendor for scoping work.
A first serious simulation pilot: €250K–€800K over 9–12 months. Includes vendor fees, cloud QPU access costs (typically €20K–€100K of that budget), internal time, and classical infrastructure. Produces one or two worked examples benchmarked against classical methods on problems drawn from the company's real portfolio.
An ongoing quantum-simulation capability in a mid-to-large enterprise: €1.5M–€5M per year, covering a 4–8 person team (mixed internal and external), one or two active vendor engagements, continuous cloud access, and participation in a relevant consortium or national programme.
The ROI timeline. Realistically, 3–7 years from initiation to a measurable impact on a product, molecule, or material that the company actually ships. This is not a two-year ROI story. It is a capability investment with optionality: you are positioning to be among the first industrial users of quantum-simulation advantage when it arrives, and to attract the domain scientists who want to work on the problem. Some leading pharma CIOs frame the investment explicitly as "the cost of being on the curve, not the cost of hitting an immediate target."
Cost signals that should worry you: a vendor promising a specific molecule, ROI, or timeline within 18 months. A vendor selling hardware as a capital purchase rather than cloud access. A vendor unwilling to benchmark against classical methods honestly. A vendor whose results do not include uncertainty estimates.
Phase 1 — Scoping and literacy (3–6 months). Executive and technical briefings tailored to your company's chemistry or materials domain. Identify 5–10 candidate problem classes from your R&D portfolio. Document the classical state-of-the-art for each. Output: an internal position paper describing where quantum simulation might plausibly help, and what evidence would change that view. Budget: €50K–€150K.
Phase 2 — Problem selection and partner scan (3–6 months). Narrow to 2–4 candidate problems with the most credible quantum fit. Engage 3–5 quantum software and platform vendors; request technical proposals and preliminary runs on small versions of the problems. Select one or two vendors for pilot work. Output: a structured pilot plan with defined benchmarks, costs, and success criteria. Budget: €80K–€200K.
Phase 3 — Pilot execution (6–12 months). Execute 1–2 pilots end-to-end: framing, hybrid workflow, quantum execution, benchmarking, analysis. Compare results to best available classical methods honestly. Evaluate platform, software, and vendor maturity. Output: a technical report, a trained internal team, and a clear go/no-go recommendation for the next phase. Budget: €250K–€800K.
Phase 4 — Scaling and capability build (12–36 months). For programmes that pass Phase 3, build a durable capability: a small permanent internal team, ongoing vendor relationships, integration with existing computational chemistry or materials workflows, selective participation in consortiums or public programmes, and a roadmap for integrating quantum results into real product decisions. Budget: €1.5M–€5M per year.
Phase 5 — Production integration (longer horizon). The stage where quantum simulation becomes a routine tool in the R&D pipeline for specific problem classes. For most organisations, this is 2029–2033, coinciding with the emergence of fault-tolerant hardware and matured application-layer software.
At every phase, maintain a credible sceptic in the room. The purpose of the programme is to answer the question "does quantum simulation help us build better products" — not to prove that quantum simulation works. The answers are different, and enterprises that conflate them waste money.
Confusing quantum simulation with quantum computing at large. The simulation use case is concentrated in chemistry, materials, and condensed-matter physics. Teams that drift into general-purpose optimisation or ML under the "quantum" banner usually underperform their chemistry-focused peers.
Over-ambitious first problems. Picking the most commercially important molecule in your pipeline for a first quantum simulation is almost always wrong. Pick a smaller, well-understood problem where classical benchmarks exist and you can verify the quantum result honestly. Scale up only after the workflow is trusted.
Ignoring classical benchmarks. The classical frontier (DFT, coupled cluster, DMRG, tensor networks, AlphaFold-style ML) keeps advancing. Running a quantum workflow without comparing to current-best-classical is intellectually empty and commercially dangerous.
Hiring physicists without domain scientists. Beautiful quantum-algorithms papers do not lead to better products. Teams succeed when domain scientists (chemists, materials scientists) are the centre of gravity and quantum specialists support them. The reverse configuration has a poor track record.
Single-platform commitment too early. Different problems fit different platforms (Rydberg, ions, superconducting, photonic). The platform race is not decided. Commit to a single vendor only after the pilot tells you which platform suits your problem class.
Treating cloud QPU hours like commodity cloud. Quantum QPU time is substantially more expensive than classical compute and is best used for targeted, high-information runs, not routine exploration. Budget and workflow design should reflect this.
Not integrating with the existing computational chemistry team. Quantum simulation is most valuable when it complements, not competes with, existing HPC chemistry workflows. Enterprises that set up their quantum team in isolation tend to build capability that never reaches product.
Silent failure of vendor commercial health. A non-trivial number of quantum-software startups have pivoted, merged, or shut down in the past three years. Include vendor financial diligence alongside technical diligence.
Engage now if: you are a pharmaceutical company with meaningful computational chemistry R&D; a chemicals or catalyst company whose products or processes involve transition-metal chemistry, strongly-correlated electron systems, or novel reaction pathways; a materials or semiconductor company developing new alloys, magnetic materials, photovoltaics, battery chemistry, or quantum-device materials; or an energy company where battery, catalyst, or photovoltaic materials sit on your innovation roadmap.
Start structured exploration within 12 months if: you are adjacent to the sectors above — specialty chemicals, agrochemicals, cosmetics with molecular-science depth, medical devices with materials-science components, aerospace-alloy programmes.
Defer if: your business is not in a chemistry-, materials-, or molecular-science-driven sector. Quantum simulation has limited relevance to financial services, retail, logistics, insurance, telecommunications, media, or most B2B services. Focus those sectors' quantum budgets on Quantum-Safe Security first, and on Quantum Sensing where applicable.
For the subset of industries where quantum simulation matters, early engagement is increasingly standard practice rather than leading-edge positioning. Competitive pharma and chemicals companies have had programmes for several years; a late 2026 start is no longer an unusual posture, but it is no longer an early one either.
Of the five quantum pillars, Quantum Simulation is the one most likely to produce the field's first undisputed, commercially-valuable quantum advantage. That moment — a molecule, catalyst, or material that is demonstrably better and whose discovery materially depended on quantum simulation — will, when it arrives, have three effects.
First, it will collapse much of the remaining public and boardroom scepticism about quantum technologies in general. "Quantum has now done a real thing" is a narrative shift that lifts funding, talent, and attention across all five pillars.
Second, it will compress the timeline for the second commercial advantage. The infrastructure and workflows that produced the first win make the second easier. Enterprises without a running programme at that point will need to stand one up quickly, under competitive pressure.
Third, it will separate the companies that invested in literacy, capability, and partnership from those that did not. This is the real strategic argument for investing now: the cost of being 18 months behind when the breakthrough arrives is materially higher than the cost of the programme today.
None of this is a reason to abandon discipline. Quantum simulation programmes must still be benchmarked against classical methods, managed with honest expectations, and integrated with existing R&D. But the strategic calculus for chemistry-, pharma-, and materials-driven industries favours running the programme over waiting.
Two longer-term directions deserve awareness, though neither is a near-term procurement decision.
Networked quantum sensors. Linking quantum sensors with entanglement allows precision beyond what any individual sensor can achieve — a technique known as distributed quantum metrology. Applications include networks of atomic clocks for geodesy, gravimeter arrays for earthquake precursor detection, and entangled telescope arrays for astronomy. This is a research-to-early-product frontier that intersects with the quantum-internet vision in our Quantum Communications pillar.
Quantum-enhanced sensing AI and software. The raw output of a quantum sensor is typically noisy and complex. Modern signal processing, ML-based denoising, and sensor-fusion techniques are as important as the sensor itself in delivering operational value. Expect the sensing ecosystem to increasingly bundle quantum hardware with sophisticated software stacks and, eventually, with AI-assisted interpretation. The competitive frontier will move partially from the sensor to the software layer.
Neither of these reframes the present procurement decision. Both are worth tracking at a strategic level.